Among patients with pulmonary arterial hypertension treated with 72-week seralutinib, those deemed responders had more improved measures, according to a poster presented at the Pulmonary Vascular ...

Pulmonary hypertension, despite advances in treatment, still has a poor prognosis, which is often associated with right heart failure, and for which pulmonary arterial hypertension (PAH) is a severe ...

Researchers from Morphic Therapeutic Inc. and affiliated organizations published data from a study that aimed to assess the potential of using arginylglycylaspartic acid (RGD) integrins for the ...

Following an admission to the authors’ centre with severe anaemia, duodenal biopsy confirmed the diagnosis of Whipple’s ...

The PAH treatment market is expected to grow from USD 5,811.5 million in 2023 to USD 7,224.4 million by 2033, at a CAGR of ...

The immune protein STAT6 may be a driver of pulmonary hypertension in people with obstructive sleep apnea, a study in mice ...

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Inhibiting GLS1 reduced high blood pressure in the right side of the heart of PAH rats and improved various measures of heart ...

The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.

Merck (MRK) is a leading global healthcare company recognized for its groundbreaking pharmaceutical products and vaccines.

Seropositive rheumatoid arthritis may be protective against the development of PAH, based on results of Mendelian randomization analyses.